NCT01936519View on ClinicalTrials.gov

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 16, 2013

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
ImmunosuppressionRenal Failure
Interventions
DRUG

Arm A: Everolimus

Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.

DRUG

Calcineurin Inhibitor

Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).

Trial Locations (1)

17033

Penn State College of Medicine; Penn State Milton S Hershey Medical Center, Hershey

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Milton S. Hershey Medical Center

OTHER